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Abstract
Aspergillosis is a spectrum of diseases caused by Aspergillus spp., which 
is a widespread fungus that produces microscopic spores. Immunocom-
petent people may breathe in numerous Aspergillus spores every day, yet 
experience no symptoms. Invasive Aspergillus sinusitis is relatively rare. 
There is limited information about the use of voriconazole for the treat-
ment of invasive Aspergillus sinusitis. Here, we present two cases of inva-
sive Aspergillus sinusitis in elderly female patients with diabetes mellitus. 
Both patients fully recovered after treatment using surgical debridement 
and an antifungal regimen that included voriconazole. [Tzu Chi Med J 2010;
22(2):106–110]
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1. Introduction
Aspergillosis is a spectrum of diseases caused by 
Aspergillus spp., a ubiquitous spore-forming sapro-
phytic thermotolerant fungus. Aspergillus spp. is 
commonly found in soil, dust, plants, and decaying veg-
etable matter. It releases microscopic airborne spores 
that can easily enter the alveoli of the lung.
Invasive aspergillosis is the most common fungal 
infection worldwide and often occurs in immuno-
compromised patients [1,2]. Common risk factors 
for aspergillosis are hemopoietic stem cell transplant-
ation, solid organ transplantation, intensive che-
motherapy, neutropenia, pulmonary disease, liver 
cirrhosis, and corticosteroid therapy [1,2]. The lung 
is the most commonly affected organ, followed by 
the liver, spleen, heart, bones, and central nervous 
system [1,2].
Invasive Aspergillus sinusitis is relatively rare [3,4]. 
This condition is treated using surgery and antifungal 
agents [3,5–7]. Previously, amphotericin B was com-
monly administered for invasive aspergillosis, but this 
drug can cause severe adverse effects [8,9]. In addi-
tion, amphotericin treatment of invasive aspergillosis 
requires intravenous (i.v.) administration, so treatment 
typically requires prolonged hospitalization.
Voriconazole is a newly-developed antifungal tri-
azole medication that is available in oral and i.v. forms. 
The drug appears to be effective in the treatment of 
patients with invasive aspergillosis [10,11], but there is 
limited knowledge about its efficacy in the treatment 
of invasive Aspergillus sinusitis. Here, we present 
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two patients with invasive Aspergillus sinusitis who 
were successfully treated using voriconazole.
2. Case reports
2.1. Case 1
A 69-year-old woman who had been diagnosed with 
diabetes mellitus and hypertension for several years 
presented with complaints of intermittent headaches 
for 3 months prior to this admission. The headaches 
progressed and she did not respond to analgesic 
medications. Five days prior to this admission, the 
vision of her right eye became blurred. Physical ex-
amination revealed impaired right visual acuity and 
right abducens nerve palsy.
A peripheral hemogram indicated a leukocyte count 
of 9.8 ˜  103/μL with 80.6% segment form, hemoglobin 
of 11.5 g/dL, mean corpuscular volume of 85.6 fL and 
platelet count of 217 × 103/μL. All electrolyte levels 
were within the reference ranges. Serum urea nitrogen 
was 25 mg/dL, creatine was 1.2 mg/dL, serum aspar-
tate aminotransferase was 37 IU/L, alanine aminotrans-
ferase was 54 IU/L, and C-reactive protein was 0.52 mg/
dL. Brain magnetic resonance imaging (MRI) with and 
without gadolinium-labeled diethylenetriamine indi-
cated an encapsulated heterogeneous cystic lesion 
in the sphenoid sinus, with invasion of the bone and 
cranial nerve (Fig. 1).
We performed transnasal endoscopic removal of the 
mass on the 4th day of hospitalization, and noted the 
presence of soft and friable necrotic tissue within 
the sphenoid sinus. Tissue culture yielded Staphyl-
ococcus aureus susceptible to oxacillin. Histopathol-
ogy indicated the presence of many uniform hyphae 
with frequent septation and dichotomous branching, 
com patible with Aspergillus spp. (Fig. 1).
We administered i.v. voriconazole and oxacillin on 
day 4. The voriconazole regimen consisted of a load-
ing dose, 6 mg/kg every 12 hours for two doses, fol-
lowed by a maintenance dose, 4 mg/kg every 12 hours. 
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Fig. 1 — (A) Brain magnetic resonance imaging shows an encapsulated heterogeneous cystic lesion in the sphenoid 
sinus with bone invasion. (B) Histological examination with hematoxylin and eosin demonstrates hemorrhaging necro-
tizing tissues (100´). Many uniform hyphae with frequent septation and dichotomous branching, compatible with 
Aspergillus spp., are seen with: (C) hematoxylin and eosin (400´); and (D) periodic acid-Schiff (400´).
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Her symptoms became milder but fever occurred on 
day 24. Serum immunoglobin M against Leptospira 
spp. (LeptoTek Lateral Flow; bioMérieux BV, Boxtel, 
The Netherlands) was weekly positive. Blood culture 
yielded Stenotrophomonas maltophilia and Coma-
monas acidovorans. We removed the central line and 
changed the antibiotics to 3 MU i.v. penicillin G every 
4 hours and 800/160 mg i.v. sulfamethoxazole/trimetho-
prim every 8 hours. After a 14-day course of penicillin 
G and sulfamethoxazole/trimethoprim and a 60-day 
course of i.v. voriconazole, her symptoms subsided. 
We changed the voriconazole to the 200 mg oral form, 
administered every 12 hours for 35 days. She was free 
of symptoms at the 8-month follow-up examination.
2.2. Case 2
A 75-year-old woman who had a history of hyperten-
sion and diabetes mellitus presented with left lower 
eyelid swelling that she had experienced for a week 
prior to this admission. The swelling progressed and 
the patient complained of local heat and tenderness. 
Physical examination indicated a tender, reddish swell-
ing of her left eyelid.
A peripheral hemogram indicated a leukocyte 
count of 25.5 × 103/μL with 82% segment and 1% 
band form, hemoglobin level of 12.8 g/dL, mean cor-
puscular volume of 92.5 fL, and platelet count of 333 × 
103/μL. Serum sodium was 130 mmol/L, potassium 
was 3.6 mmol/L, urea nitrogen was 21 mg/dL, creat-
ine was 0.5 mg/dL, aspartate aminotransferase was 
20 IU/L, alanine aminotransferase was 26 IU/L, and 
C-reactive protein was 0.52 mg/dL. Computed tom-
ography indicated the presence of an expansile soft 
tissue mass in the left maxillary, frontal, and ethmoid 
sinuses (Fig. 2).
We initially administered i.v. penicillin and cefepime. 
These were not effective, so debridement was per-
formed on day 3. Histopathology indicated the pres-
ence of many uniform hyphae with frequent septation 
and dichotomous branching as well as invasion of 
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Fig. 2 — Computed tomography shows an expansile soft tissue mass in the left: (A) ethmoid sinuses; and (B) sphenoid 
sinuses. Histological examination with hematoxylin and eosin demonstrates: (C) necrotizing tissues at low magnifica-
tion of 100´; and (D) many uniform hyphae compatible with invasive aspergillosis at high magnification of 400´.
 TZU CHI MED J  June 2010  Vol 22  No 2 109
tissue, which was compatible with invasive aspergil-
losis (Fig. 2). Pus and tissue culture yielded Klebsiella 
pneumoniae.
We administered 5 mg/kg i.v. liposomal amphoter-
icin B per day after the operation and changed it to 
i.v. voriconazole on day 6. The voriconazole regimen 
consisted of a loading dose, 6 mg/kg every 12 hours 
for two doses, followed by a maintenance dose, 4 mg/
kg every 12 hours. Serum immunoglobin M against 
Leptospira spp. (LeptoTek Lateral Flow; bioMérieux 
BV) was weakly positive. The patient’s low-grade fever 
persisted, so we performed a second debridement 
on day 13, after which her fever subsided. Sinoscopy, 
performed on day 21, indicated clarity of the left max-
illary and frontal sinuses. We discontinued i.v. peni-
cillin and cefepime on day 21, and discharged the 
patient on day 25, at which time we prescribed 200 mg 
oral voriconazole every 12 hours for 28 days. The pa-
tient was free of symptoms at the 18-month follow-up 
examination.
3. Discussion
Aspergillus is very common in the daily environ-
ment and is the leading cause of fungal sinusitis [12]. 
A. fumigatus is the most common species involved, 
followed by A. flavus, A. niger and A. terreus [13–15]. 
Most immunocompetent patients who experience sinus 
colonization by Aspergillus spp. remain symptom-free. 
Invasive aspergillosis typically occurs in immunocom-
promised patients, such as those with hematological 
malignancy, neutropenia, steroid exposure, diabetes 
mellitus, and liver disease [1,2]. The diagnosis of 
Aspergillus sinusitis is often delayed, particularly in 
immunocompetent patients. The most common symp-
toms of aspergillosis are headaches, proptosis, nasal 
obstruction, decreased visual acuity, retro-orbital pain, 
epistaxis, diplopia, and sinus or facial tenderness [3]. 
Aspergillosis should be suspected in patients with 
refractory or recurrent sinusitis [5]. In the two cases 
described here, one patient presented with right ab-
ducens nerve palsy and the other with swelling of 
the left lower eyelid. Although both patients had dia-
betes mellitus, their otherwise normal immunological 
statuses did not lead physicians to initially suspect 
aspergillosis.
The typical appearance of fungal sinusitis on com-
puted tomography is a central radio-opaque lesion, 
which is possibly related to calcium phosphate deposi-
tion in necrotic areas [12,16,17]. The decreased sig-
nal intensity on T1-weighted MRI and much decreased 
signal intensity on T2-weighted MRI seem to be char-
acteristic of mycetomas [18]. Positive culture results 
from sterile sites consistent with infection are needed 
but the urine and mucous membranes should be ex-
cluded [19]. Definite diagnosis of invasive Aspergillus 
sinusitis requires positive histopathological or cyto-
pathological examination results. In both of our cases, 
evidence of hyphae and associated tissue damage in 
the biopsy specimens were consistent with the diag-
nosis of invasive Aspergillus sinusitis.
Standard treatment of invasive aspergillosis sinusi-
tis includes surgical debridement and administration 
of antifungal agents [3,5]. Amphotericin B is com-
monly administered for the treatment of invasive as-
pergillosis [20–22], but may be associated with many 
adverse effects [8,9]. In addition, amphotericin is 
only available in the i.v. form, so prolonged hospitali-
zation may be required. Voriconazole, a cytochrome 
P450-dependent 14-α-sterol demethylase inhibitor, 
has excellent activity against Aspergillus spp. in vitro 
and the oral bioavailability is greater than 90%. After 
the i.v. loading regimen, patients can be given oral 
voriconazole, with no need for hospitalization [23]. 
A previous randomized and unblinded trial that com-
pared voriconazole and amphotericin B for the treat-
ment of aspergillosis showed that voriconazole was 
associated with better responses and survival rates, 
as well as fewer side effects [24]. The most common 
adverse effects of voriconazole are transient visual 
disturbance, abnormal liver enzymes, photosensitivity 
and skin rashes, but these typically resolve when the 
drug is discontinued. We treated both of our patients 
with surgical debridement and adjuvant antifungal 
agents. In one patient, we administered i.v. voricona-
zole initially; in the other patient, we first administered 
liposomal amphotericin B, and then changed to vori-
conazole. Both patients tolerated the voriconazole well 
and eventually recovered from the invasive Aspergillus 
sinusitis.
Both of our patients tested positive for serum im-
munoglobulin M against Leptospira spp. We are un-
sure whether these positive responses are meaningful, 
or are merely false-positive responses due to the 
lack of result on the microscopic agglutination tests. 
Invasive aspergillosis was reported in the autopsies 
of three patients with leptospirosis [25]. Another re-
searcher identified invasive pulmonary and cerebral 
aspergillosis in a patient with leptospirosis [26]. None 
of the patients were in severe immunocompromised 
states. The immune statuses of the two patients pre-
sented here, who both tested positive for Leptospira, 
were not bad enough to suggest invasive aspergillosis. 
However, leptospirosis can lead to vasculitis and 
consumptive coagulopathy [27], thus possibly increas-
ing the permeability of vessels and allowing colo-
nized Aspergillus spp. to invade nearby tissues. Such 
a mechanism may explain why invasive aspergillosis 
is occasionally found in immunocompetent p atients 
[28–30].
In conclusion, we have presented two rare cases 
of invasive Aspergillus sinusitis. Aspergillus spp. in-
vaded the sphenoidal sinus of one patient and multiple 
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sinuses in the other patient. We successfully treated 
both patients using surgical debridement and anti-
fungal regimens that included voriconazole. Both pa-
tients tested positive for immunoglobulins against 
Leptospira spp. Thus, we suggest that future clinical 
studies examine the relationship between invasive 
aspergillosis and leptospirosis.
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